Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA.
Arch Pathol Lab Med. 2011 Aug;135(8):984-93. doi: 10.5858/2010-0515-OAR1.
Medulloblastomas (MBs) and atypical teratoid/rhabdoid tumors (AT/RTs) arising in infants and children can be difficult to distinguish; however, histologic characterization is prognostically important.
To determine histologic and phenotypic markers associated with utility with progression-free survival (PFS) and overall survival (OS) in children younger than 3 years with MBs and AT/RTs.
We undertook a histologic and immunophenotypic study of MBs and AT/RTs arising in infants and children younger than 3 years treated in a Pediatric Brain Tumor Consortium study. The 41 girls and 55 boys ranged in age from 2 to 36 months at enrollment. These infants and children exhibited 51 MBs, 26 AT/RTs, and 24 other tumors (not further studied). Median follow-up of the patients was 17.2 months from diagnosis (range: 1.4-93 months).
Infants and children with AT/RT exhibited a statistically significant shorter PFS and OS when compared to infants and children with MBs (both P < .001). A lack of nuclear BAF47 immunohistochemical reactivity proved reliable in identifying AT/RTs. Among MBs, our data suggest an association of nodularity and prolonged PFS and OS, which must be independently confirmed. Anaplasia correlated with OTX2 reactivity and both OTX2 and moderate to severe anaplasia correlated with PFS but not with OS.
Distinguishing AT/RT from MBs is clinically important. For expert neuropathologists, the diagnoses of AT/RT and MB can be reliably made from hematoxylin-eosin stains in the vast majority of cases. However certain rare small cell variants of AT/RT can be confused with MB. We also found that immunohistochemical reactivity for BAF47 is clinically useful in distinguishing MBs from AT/RTs and for identifying certain small cell AT/RTs. Among MBs, nodularity may be an important prognostic factor for improved PFS and OS in infants and children.
婴儿和儿童中发生的髓母细胞瘤(MBs)和非典型畸胎瘤/横纹肌样瘤(AT/RTs)可能难以区分;然而,组织学特征对预后具有重要意义。
确定与婴儿和儿童(年龄小于 3 岁)MBs 和 AT/RTs 的无进展生存期(PFS)和总生存期(OS)相关的组织学和表型标志物。
我们对在儿科脑肿瘤联盟研究中治疗的年龄小于 3 岁的婴儿和儿童中发生的 MBs 和 AT/RTs 进行了组织学和免疫表型研究。41 名女孩和 55 名男孩的入组年龄为 2 至 36 个月。这些婴儿和儿童中,51 例为 MBs、26 例为 AT/RTs、24 例为其他肿瘤(未进一步研究)。从诊断到患者中位随访时间为 17.2 个月(范围:1.4-93 个月)。
与 MBs 相比,AT/RT 患儿的 PFS 和 OS 明显较短(均 P<.001)。核 BAF47 免疫组化反应缺失可靠地识别出 AT/RTs。在 MBs 中,我们的数据表明结节性与延长的 PFS 和 OS 相关,这需要独立确认。间变与 OTX2 反应性相关,而 OTX2 和中度至重度间变均与 PFS 相关,与 OS 无关。
区分 AT/RT 和 MBs 具有临床重要性。对于专家神经病理学家来说,在绝大多数情况下,从苏木精-伊红染色中可以可靠地做出 AT/RT 和 MB 的诊断。然而,某些罕见的小细胞 AT/RT 变体可能与 MB 混淆。我们还发现,BAF47 的免疫组化反应在区分 MBs 和 AT/RTs 以及识别某些小细胞 AT/RTs 方面具有临床实用性。在 MBs 中,结节性可能是改善婴儿和儿童 PFS 和 OS 的重要预后因素。